Oscient Pharmaceuticals Corp. (OSCI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jeff Lee who wrote (8)	5/28/1996 12:18:00 AM
From: Tara Cobble	of 1154

Jeff, Glad to here you held on for the run up. Like I said I would expect to see further run up over the next 12 to 18 months for patient investors. There are several trends that I like and believe to be very promising. 1) GENE has lost money for the four years 91-94, and it was not great losses only like 12 cents/share, 16 cents/share, 33 cents/share (not the exact numbers for the years but close enough for this discussion) and then in 1995 they made 5 cents/share. 2) The last quarter was a profit of 15 cents/share. 3) Last year they signed two collaberative agreements: August 95 with Astra AB Dec. 95 with Schering - Plough 4) The positive comments from USA Today article and fund manager in my earlier post. 5) My Broker has been good with these types of recommendations. I was in GENE earlier for a very good profit, and expect to hold on longer term this time. The news since my investment last year is looking even brighter, so I think it can keep going up. 6) Brokerage firms don't usually publish recommendations on stocks when they are speculative and losing money. GENE made money last year and has followed with a very good quarter (3x all of last year). I would expect things can only go up from here and more following with brokerage houses and respect from the Biotech community. 7) The way things looked last week to me is that GENE has a base around $9 to $10 so you should feel safe with this investment over the next year+. Of course these are only my semi-educated guesses, but I think they carry more common sense than a so called WSJ writer publishing an article on IOMG hype. (I only say this because I am one of the IOMG investors that is bucking the trend and watching my investment grow daily/weekly.) Sorry, I don't know anything about AMLN, ARRS, and RZYM. Can you compare these companies side by side with GENE and see which is more attractive. You can get into sec.gov to look at the SEC documents on companies and may help you out. Good Luck Tara ;-)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next